Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
RLYB

RLYB - Rallybio Corporation Stock Price, Fair Value and News

$0.640.00 (0.00%)
Market Closed

57/100

RLYB

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

57/100

RLYB

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$0.76

Target 3M

$0.69

Target 6M

$0.71

RLYB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

RLYB Price Action

Last 7 days

-5.9%

Last 30 days

-8.6%

Last 90 days

-8.6%

Trailing 12 Months

-28.1%

RLYB RSI Chart

RLYB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

RLYB Valuation

Market Cap

27.0M

Price/Earnings (Trailing)

-1.91

Price/Sales (Trailing)

45.06

EV/EBITDA

0.4

Price/Free Cashflow

-0.77

RLYB Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$0.76

Target 3M

$0.69

Target 6M

$0.71

RLYB Fundamentals

RLYB Revenue

Revenue (TTM)

600.0K

Rev. Growth (Yr)

-53.14%

Rev. Growth (Qtr)

-11.66%

RLYB Earnings

Earnings (TTM)

-14.2M

Earnings Growth (Yr)

239.68%

Earnings Growth (Qtr)

265.06%

RLYB Profitability

EBT Margin

-2144.33%

Return on Equity

-22.48%

Return on Assets

-20.94%

Free Cashflow Yield

-129.44%

RLYB Investor Care

Shares Dilution (1Y)

1.82%

Diluted EPS (TTM)

-0.31

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250000
20245.9M5.4M4.9M600.0K
20233.4M4.8M5.8M6.1M
2022134.0K391.0K904.0K2.0M
2021141.8K112.5K83.3K54.0K
2020000171.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Rallybio Corporation

RLYB
Rallybio Corporation, a clinical-stage biotechnology company, engages in identifying, accelerating, and development of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
 CEO
 WEBSITErallybio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES45

Rallybio Corporation Frequently Asked Questions

RLYB is the stock ticker symbol of Rallybio Corporation. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Rallybio Corporation is 27.04 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check RLYB's fair value in chart for subscribers.

The fair value guage provides a quick view whether RLYB is over valued or under valued. Whether Rallybio Corporation is cheap or expensive depends on the assumptions which impact Rallybio Corporation's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RLYB.

As of Wed Jan 28 2026, RLYB's PE ratio (Price to Earnings) is -1.91 and Price to Sales (PS) ratio is 45.06. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RLYB PE ratio will change depending on the future growth rate expectations of investors.